Carroll Investors’s Gilead Sciences GILD Stock Holding History

Carroll Investors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-78	Closed	-$4K	–	83
2022 Q1	$4K	Hold	78	–	–	﹤0.01%	147
2021 Q4	$5K	Buy	+78	New	+$5.37K	﹤0.01%	160

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carroll Investors's GILD Position: Q2 2022 in Review

Carroll Investors sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 78 shares — an estimated $4K sold.

Carroll Investors first reported a position in GILD in Q4 2021 and held it in 2 quarters. The position peaked at $5K in Q4 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

Carroll Investors reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
Carroll Investors sold 78 Gilead Sciences shares in Q2 2022, an estimated $4K.
Carroll Investors first reported a position in Gilead Sciences in Q4 2021 and held it in 2 quarters.
Carroll Investors's Gilead Sciences position peaked at $5K in Q4 2021.
1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.